Triumvira is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics built on its proprietary T cell Antigen Coupler (TAC) platform. The TAC receptor is a multi-domain chimeric molecule that interacts with the natural T cell receptor to help T cells recognize and eliminate tumor cells. Proceeds from the financing will support continued preclinical and clinical development of Triumvira’s TAC-T cell therapy programs. The company’s lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial (TACTIC-2) for patients with HER2-overexpressing solid tumors, including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers. Triumvira said it plans to advance its pipeline through 2022 and beyond. The company is headquartered in Austin, Texas with research facilities in Hamilton, Ontario. Triumvira Immunologics develops a proprietary T-cell Antigen Coupler (TAC) platform that recruits the natural T-cell receptor to target cancers independent of MHC. The company positions TAC-T cells as differentiated from second-generation CAR-Ts, reporting preclinical absence of tonic signaling, strong tumor penetration, long-term persistence, and no evidence of toxicity in models. Triumvira is advancing both autologous and allogeneic programs and plans to move multiple programs into the clinic for solid tumors and hematologic malignancies. The company describes TAC as a hybrid molecule combining tumor-targeting domains with T-cell activation machinery to broaden applicability across patient populations. Triumvira is clinical stage and operates corporate offices in Austin, Texas, with research facilities in Hamilton, Ontario. The company emphasizes development of therapies intended to be safer and more efficacious than current CAR and engineered TCR approaches.

Total raised

$55M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2020